Literature DB >> 29913322

Culture supernatants of oral cancer cells induce impaired IFN-α production of pDCs partly through the down-regulation of TLR-9 expression.

Nannan Han1, Zun Zhang2, Houyu Jv3, Jingzhou Hu4, Min Ruan5, Chenping Zhang3.   

Abstract

OBJECTIVES: The aim of the present study was to investigate whether tumor-derived supernatants down-regulate the immune function of plasmacytoid dendritic cells (pDCs) in oral cancer and the potential molecular mechanisms of this effect.
MATERIALS AND METHODS: Immunohistochemistry (IHC) and flow cytometry were used to detect tumor-infiltrating and peripheral blood pDCs. MTS and flow cytometry were employed to evaluate the immune response of CD4+ T cells. Real-time PCR and ELISA assays were used to identify TLR-7 and TLR-9 expression, IFN-α production and tumor-secreted soluble cytokines.
RESULTS: The proportion of pDCs (0.121%±0.043%) was significantly higher in Oral squamous cell carcinoma (OSCC) samples than in normal tissue (0.023%±0.016%) (P = 0.021). TLR9 mRNA was significantly lower in tumor-infiltrating pDCs and positively correlated to low IFN-α production (r = 0.956; P<0.01). The supernatant of oral cancer cells negatively regulated TLR9 mRNA expression and the subsequent IFN-α production of pDCs, which inhibited the immune response of CD4+ T cells. The neutralizing antibodies blocking assay showed that the specific inhibitory effect of pDC functionality was associated with the soluble fraction of the oral cancer environment, which is mainly mediated by IL-10 and TGF-β cooperation.
CONCLUSION: Tumor-derived supernatants may impair the function of tumor-infiltrating pDCs, which subsequently decreases the immune response of CD4+ T cells in human oral cancer through TGF-β- and IL-10- dependent mechanisms. Careful manipulation of these impaired pDCs may help develop an important alternative immunotherapy for the treatment of oral cancer.
Copyright © 2018 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  CD4(+)T cell; Interferon-alpha (IFN-α); Oral cancer; Plasmacytoid dendritic cells (pDCs); Toll-like receptor-9 (TLR-9)

Mesh:

Substances:

Year:  2018        PMID: 29913322     DOI: 10.1016/j.archoralbio.2018.06.006

Source DB:  PubMed          Journal:  Arch Oral Biol        ISSN: 0003-9969            Impact factor:   2.633


  6 in total

Review 1.  Human Plasmacytoid Dendritic Cells and Cutaneous Melanoma.

Authors:  Matilde Monti; Francesca Consoli; Raffaella Vescovi; Mattia Bugatti; William Vermi
Journal:  Cells       Date:  2020-02-11       Impact factor: 6.600

2.  Increased tumor-infiltrating plasmacytoid dendritic cells promote cancer cell proliferation and invasion via TNF-α/NF-κB/CXCR-4 pathway in oral squamous cell carcinoma.

Authors:  Nannan Han; Xing Li; Yupu Wang; Lin Wang; Chunye Zhang; Zun Zhang; Min Ruan; Chenping Zhang
Journal:  J Cancer       Date:  2021-03-19       Impact factor: 4.207

Review 3.  Type I Interferon Production of Plasmacytoid Dendritic Cells under Control.

Authors:  Dóra Bencze; Tünde Fekete; Kitti Pázmándi
Journal:  Int J Mol Sci       Date:  2021-04-18       Impact factor: 5.923

4.  Early antitumor activity of oral Langerhans cells is compromised by a carcinogen.

Authors:  Yasmin Saba; Itay Aizenbud; Daniela Matanes; Noam Koren; Or Barel; Khalid Zubeidat; Tal Capucha; Eyal David; Luba Eli-Berchoer; Patrizia Stoitzner; Asaf Wilensky; Ido Amit; Rakefet Czerninski; Simon Yona; Avi-Hai Hovav
Journal:  Proc Natl Acad Sci U S A       Date:  2022-01-18       Impact factor: 12.779

5.  Predictive value of plasmacytoid dendritic cells and Toll-like receptor-9 regarding the treatment efficacy of interferon-α in HBeAg-positive chronic hepatitis B patients.

Authors:  Yue Chen; Jia-En Yang; Jing-Mo Tang; Qian-Guo Mao; Qi-Zhong Zheng; Ying Zheng
Journal:  Exp Ther Med       Date:  2019-11-01       Impact factor: 2.447

6.  Plasmacytoid Dendritic Cell Impairment in Metastatic Melanoma by Lactic Acidosis.

Authors:  Matilde Monti; Raffaella Vescovi; Francesca Consoli; Davide Farina; Daniele Moratto; Alfredo Berruti; Claudia Specchia; William Vermi
Journal:  Cancers (Basel)       Date:  2020-07-28       Impact factor: 6.639

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.